NCT01320891 is a NA clinical trial of balanced solutions in Large Bowel Cancer, sponsored by Università degli Studi di Ferrara.

Who is sponsoring NCT01320891?

NCT01320891 is sponsored by Università degli Studi di Ferrara.

What drugs are being tested in NCT01320891?

Interventions in NCT01320891: balanced solutions, not balanced.

What condition does NCT01320891 study?

NCT01320891 studies Large Bowel Cancer.

Is NCT01320891 still recruiting?

NCT01320891 is currently completed. Last updated 3 May 2017.

Last reviewed 2017-05-03 · How we verify

NCT01320891

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators

Completed NA Last updated 3 May 2017

What this trial tests

NA trial testing balanced solutions in Large Bowel Cancer in 40 participants. Completed in 1 February 2012.

Timeline

1 February 2010

Primary endpoint
1 August 2011

1 February 2012

Quick facts

Lead sponsor	Università degli Studi di Ferrara
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	1 February 2010
Primary completion	1 August 2011
Estimated completion	1 February 2012
Sites	1 location across Italy

Drugs / interventions tested

balanced solutions
not balanced

Conditions studied

Large Bowel Cancer — all drugs for Large Bowel Cancer →

Sponsor

Università degli Studi di Ferrara — full company profile →

Who can join

Adults 18 to 90, any sex, with Large Bowel Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

acid/base disorder
Time frame: T0: anaesthesia induction (control value) T1: end of surgery T2: 1h after the end of surgery T3: 24h after the beginning of surgery
the investigators assess difference in acid base disorders between the two groups measuring emogas analyses data and blood electrolites levels at the same time (two days)

Sponsor's own description

Aim of the study is to ascertain whether a different strategy of fluids administration can be responsible of differences in terms of acid/base disorders (Stewart approach), pro-inflammatory and inflammatory mediators. Hence two groups of patients will be treated either with not-balanced solutions (Normal Saline) or balanced solutions

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of two different strategies of fluid administration on inflammatory mediators, plasma electrolytes and acid/base disorders in patients undergoing major abdominal surgery: a randomized double blind study.
Volta CA, Trentini A, Farabegoli L, Manfrinato MC, et al · · 2013 · cited 23× · PMID 24059479 · DOI 10.1186/1476-9255-10-29

Verify or expand the search:

Other Università degli Studi di Ferrara trials

Trials by the same sponsor.

NCT07157696 — Advanced Respiratory Monitoring and Oxygen Therapy in Chronically Ill Patients With Acute Respiratory Failure · NA · not yet recruiting
NCT06671106 — Efficacy of an Amine and Zinc Lactate - Containing Mouthrinse in the Home-based Treatment of Plaque-induced Gingivitis i · NA · recruiting
NCT06482294 — CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma · Phase 2 · active not recruiting
NCT06215001 — Individualized Selection of PEEP in Patients Affected by Expiratory Flow Limitation · NA · unknown
NCT06769308 — Effect of Goal-directed Analgesia and Sedation Using EEG Derived QCON/qNOX in ICU Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01320891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Università degli Studi di Ferrara
Last refreshed: 3 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01320891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing